Cargando…

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

INTRODUCTION: The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ), tau and phosphorylated tau (p-tau181) are now used for the diagnosis of Alzheimer’s disease (AD). Aβ40 is the most abundant Aβ peptide isoform in the CSF, and the Aβ 42/40 ratio has been proposed to better reflect brain amyloid p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dumurgier, Julien, Schraen, Susanna, Gabelle, Audrey, Vercruysse, Olivier, Bombois, Stéphanie, Laplanche, Jean-Louis, Peoc’h, Katell, Sablonnière, Bernard, Kastanenka, Ksenia V, Delaby, Constance, Pasquier, Florence, Touchon, Jacques, Hugon, Jacques, Paquet, Claire, Lehmann, Sylvain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450486/ https://www.ncbi.nlm.nih.gov/pubmed/26034513 http://dx.doi.org/10.1186/s13195-015-0114-5

Ejemplares similares

A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles
por: Lehmann, Sylvain, et al.
Publicado: (2014)

New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
por: Rose, Christiane, et al.
Publicado: (2012)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ(1–42) and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
por: Duron, Emmanuelle, et al.
Publicado: (2018)

Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß(1−42), and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
por: Duron, Emmanuelle, et al.
Publicado: (2019)

Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease
por: Dumurgier, Julien, et al.
Publicado: (2013)

Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer’s Disease
por: Paquet, Claire, et al.
Publicado: (2015)

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM(R) Scale
por: Lehmann, Sylvain, et al.
Publicado: (2018)

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
por: Lehmann, Sylvain, et al.
Publicado: (2020)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

Central Nervous System and Peripheral Inflammatory Processes in Alzheimer’s Disease: Biomarker Profiling Approach
por: Delaby, Constance, et al.
Publicado: (2015)

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
por: Cognat, Emmanuel, et al.
Publicado: (2019)

Neglected Comorbidity of Chronic Heart Failure: Iron Deficiency
por: Manceau, Hana, et al.
Publicado: (2022)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

Iron deficiency markers in patients undergoing iron replacement therapy: a 9-year retrospective real-world evidence study using healthcare databases
por: Cacoub, Patrice, et al.
Publicado: (2020)

PKR involvement in Alzheimer’s disease
por: Hugon, Jacques, et al.
Publicado: (2017)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Genotyping Test with Clinical Factors: Better Management of Acute Postoperative Pain?
por: Hajj, Aline, et al.
Publicado: (2015)

Ferroptosis in Liver Diseases: An Overview
por: Capelletti, Martina Maria, et al.
Publicado: (2020)

Iron Metabolism in Normal and Pathological Pregnancies and Fetal Consequences
por: Mégier, Charles, et al.
Publicado: (2022)

Sample Pooling and Inflammation Linked to the False Selection of Biomarkers for Neurodegenerative Diseases in Top–Down Proteomics: A Pilot Study
por: Molinari, Nicolas, et al.
Publicado: (2018)

Blood-Based Kinase Assessments in Alzheimer’s Disease
por: Hugon, Jacques, et al.
Publicado: (2018)

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
por: Marelli, Cecilia, et al.
Publicado: (2015)

A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging
por: Dumurgier, Julien, et al.
Publicado: (2022)

Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study
por: Paquet, Claire, et al.
Publicado: (2016)

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

Smoking Induces Long-Lasting Effects through a Monoamine-Oxidase Epigenetic Regulation
por: Launay, Jean-Marie, et al.
Publicado: (2009)

Smoking Related Diseases: The Central Role of Monoamine Oxidase
por: Rendu, Francine, et al.
Publicado: (2011)

Patients with COVID-19 present with low plasma citrulline concentrations that associate with systemic inflammation and gastrointestinal symptoms
por: Uzzan, Mathieu, et al.
Publicado: (2020)

Reversible atransferrinemia in a patient with chronic enteropathy: is transferrin mandatory for iron transport?
por: Raynor, Alexandre, et al.
Publicado: (2022)

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
por: Delaby, Constance, et al.
Publicado: (2021)

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
por: Boumenir, Adla, et al.
Publicado: (2019)

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study
por: Saddiki, Hana, et al.
Publicado: (2020)

Impact of pain on cognitive functions in primary Sjögren syndrome with small fiber neuropathy: 10 cases and a literature review
por: Indart, Sandrine, et al.
Publicado: (2017)

Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years
por: Stoeck, Katharina, et al.
Publicado: (2012)

Regulating Factors of PrP(res) Glycosylation in Creutzfeldt-Jakob Disease - Implications for the Dissemination and the Diagnosis of Human Prion Strains
por: Levavasseur, Etienne, et al.
Publicado: (2008)

Correction: Regulating Factors of PrP(res) Glycosylation in Creutzfeldt-Jakob Disease - Implications for the Dissemination and the Diagnosis of Human Prion Strains
por: Levavasseur, Etienne, et al.
Publicado: (2008)

617. Efficacy of Dimercaptosuccinic Acid (DMSA), a Zinc Chelator, in Combination with Imipenem Against Metallo-β-Lactamase Producing Escherichia coli in a Murine Peritonitis Model
por: Cheminet, Geoffrey, et al.
Publicado: (2019)

Kinetics of serum hepcidin and interleukin-6 levels following COVID-19 infection in hemodialysis patients
por: Touzot, Maxime, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f98u3586vnal0a621cs5603apt